Spots Global Cancer Trial Database for stage iv adult burkitt lymphoma

Every month we try and update this database with for stage iv adult burkitt lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma	NCT00005959	Lymphoma	filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	18 Years -	National Cancer Institute (NCI)
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00019708	Extranodal Marg... Nodal Marginal ... Non-Hodgkin Lym... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu...	tanespimycin	19 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia	NCT00040690	Leukemia Lymphoma	filgrastim cyclophosphamid... cytarabine doxorubicin hyd... etoposide ifosfamide leucovorin calc... methotrexate vincristine sul... radiation thera...	16 Years -	National Cancer Institute (NCI)
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease	NCT00176475	Leukemia Lymphoma Multiple Myelom...	rituximab therapeutic all...	18 Years -	Rutgers, The State University of New Jersey
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma	NCT00244946	Lymphoma	therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo...	15 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	NCT00101244	Adult Grade III... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202	NCT00896662	Lymphoma Solid Tumor	immunologic tec... laboratory biom... pharmacological...	18 Years -	Vanderbilt-Ingram Cancer Center
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases	NCT00376519	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo...	cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra...	18 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma	NCT00981097	Lymphoma Nonneoplastic C...	polymerase chai... laboratory biom...	18 Years -	AIDS Malignancy Consortium
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00082823	Cancer	ziv-aflibercept	18 Years - 120 Years	Regeneron Pharmaceuticals
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia	NCT00002494	Leukemia Lymphoma	cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... etoposide ifosfamide leucovorin calc... mesna methotrexate prednisone therapeutic hyd... vincristine sul... low-LET cobalt-... low-LET photon ...	15 Years -	Alliance for Clinical Trials in Oncology
Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia	NCT00040690	Leukemia Lymphoma	filgrastim cyclophosphamid... cytarabine doxorubicin hyd... etoposide ifosfamide leucovorin calc... methotrexate vincristine sul... radiation thera...	16 Years -	National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma	NCT00003397	Lymphoma	filgrastim rituximab sargramostim carmustine cisplatin cyclophosphamid... dexamethasone etoposide gemcitabine hyd... melphalan paclitaxel bone marrow abl... peripheral bloo...	18 Years - 75 Years	University of Maryland, Baltimore
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers	NCT00003572	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma	NCT00002471	Leukemia Lymphoma	asparaginase cyclophosphamid... cytarabine daunorubicin hy... dexamethasone etoposide leucovorin calc... methotrexate methylprednisol... therapeutic hyd... thiotepa vincristine sul...	-	Memorial Sloan Kettering Cancer Center
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT01045928	Adult Non-Hodgk... Adult Grade III... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenstrom Mac...	lenalidomide rituximab polymerase chai... nucleic acid se... polymorphism an... flow cytometry laboratory biom...	18 Years -	Case Comprehensive Cancer Center
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	NCT00010192	B-cell Adult Ac... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ...	rituximab aldesleukin laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer	NCT00296023	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo...	18 Years - 75 Years	University of California, San Francisco
PS-341 in Treating Patients With Advanced Cancer	NCT00006362	Leukemia Lymphoma Multiple Myelom... Precancerous Co... Unspecified Adu...	bortezomib	18 Years -	Mayo Clinic
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer	NCT00290641	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic...	filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera...	- 45 Years	Masonic Cancer Center, University of Minnesota
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies	NCT01564277	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Contiguous Stag... de Novo Myelody... Noncontiguous S... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Adult... Stage I Adult B... Stage III Adult... Stage IV Adult ... Untreated Adult... Untreated Adult...	rasburicase allopurinol	18 Years -	Roswell Park Cancer Institute
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	NCT00275080	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Secondary Acute... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Untreated Adult... Untreated Adult...	vorinostat decitabine	18 Years -	National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Advanced Hematologic Cancer	NCT00005967	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	tipifarnib	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma	NCT00002576	Lymphoma	cyclophosphamid... doxorubicin hyd... mitoxantrone hy... prednisolone vincristine sul...	65 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia	NCT00005977	Leukemia Lymphoma	filgrastim cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... etoposide ifosfamide leucovorin calc... methotrexate vincristine sul...	- 22 Years	Children's Oncology Group
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia	NCT00004084	Leukemia Lymphoma	indium In 111 L... yttrium Y 90 ep...	18 Years -	Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma	NCT00018954	Leukemia Lymphoma	asparaginase cyclophosphamid... cytarabine daunorubicin hy... doxorubicin hyd... etoposide ifosfamide mercaptopurine methotrexate prednisone vincristine sul... conventional su... radiation thera...	-	National Institutes of Health Clinical Center (CC)
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer	NCT00004061	Leukemia Lymphoma Oral Complicati...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera...	18 Years - 65 Years	National Cancer Institute (NCI)
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy	NCT00006220	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	arsenic trioxid... tretinoin	15 Years -	Washington University School of Medicine
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer	NCT00004061	Leukemia Lymphoma Oral Complicati...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera...	18 Years - 65 Years	National Cancer Institute (NCI)
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma	NCT00036946	Lymphoma Unspecified Adu...	ziv-aflibercept	25 Years - 120 Years	Regeneron Pharmaceuticals
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma	NCT00045266	Lymphoma Unspecified Adu...	ziv-aflibercept	25 Years - 120 Years	Regeneron Pharmaceuticals
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia	NCT00039130	Leukemia Lymphoma	filgrastim rituximab cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... etoposide ifosfamide leucovorin calc... methotrexate prednisone vincristine sul... Allopurinol	16 Years -	Alliance for Clinical Trials in Oncology
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma	NCT00244946	Lymphoma	therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo...	15 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00083213	Cancer	ziv-aflibercept	18 Years - 120 Years	Regeneron Pharmaceuticals
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT00725062	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	CD4+CD25+ regul... allogeneic hema...	18 Years - 70 Years	Masonic Cancer Center, University of Minnesota
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma	NCT00244946	Lymphoma	therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo...	15 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer	NCT00005993	Breast Cancer Lymphoma	aldesleukin filgrastim recombinant hum... peripheral bloo...	18 Years - 65 Years	Masonic Cancer Center, University of Minnesota
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT00725062	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	CD4+CD25+ regul... allogeneic hema...	18 Years - 70 Years	Masonic Cancer Center, University of Minnesota
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma	NCT00443976	Non-Hodgkins Ly... Unspecified Adu...	Aurora kinase i...	18 Years -	Canadian Cancer Trials Group
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00019708	Extranodal Marg... Nodal Marginal ... Non-Hodgkin Lym... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu...	tanespimycin	19 Years -	National Cancer Institute (NCI)
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	NCT00101244	Adult Grade III... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma	NCT00004039	Lymphoma	recombinant int... rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	-	Hoag Memorial Hospital Presbyterian
Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma	NCT00559104	Lymphoma	carmustine cyclophosphamid... etoposide autologous hema... peripheral bloo... total-body irra... G-CSF	16 Years - 59 Years	City of Hope Medical Center
Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma	NCT00726700	Lymphoma	pegfilgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	61 Years - 80 Years	Universität des Saarlandes
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma	NCT00004039	Lymphoma	recombinant int... rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	-	Hoag Memorial Hospital Presbyterian
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia	NCT00133991	Leukemia Lymphoma	Filgrastim Rituximab Cyclophosphamid... Cytarabine Methotrexate Prednisone Hydrocortisone Vincristine Leucovorin	30 Years - 120 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma	NCT02037256	Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Refractory Mult... Small Intestine... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Multipl... Stage I Small L... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Untreated Hairy... Waldenström Mac...	bortezomib filgrastim autologous hema...	18 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma	NCT00004039	Lymphoma	recombinant int... rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	-	Hoag Memorial Hospital Presbyterian
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer	NCT00004132	Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... Oral Complicati... Radiation Toxic...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide quality-of-life... radiation thera...	12 Years - 65 Years	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma	NCT00559104	Lymphoma	carmustine cyclophosphamid... etoposide autologous hema... peripheral bloo... total-body irra... G-CSF	16 Years - 59 Years	City of Hope Medical Center
VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL	NCT00274794	Lymphoma	filgrastim rituximab	18 Years -	The Cleveland Clinic
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma	NCT00003337	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma	NCT00004260	Lymphoma	recombinant int... rituximab	18 Years -	Mayo Clinic
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder	NCT00064246	Post-transplant... Recurrent Adult... Recurrent Adult... Stage III Adult... Stage III Adult... Stage IV Adult ... Stage IV Adult ... Waldenström Mac...	rituximab indium In 111 i... yttrium Y 90 ib...	18 Years -	National Cancer Institute (NCI)
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia	NCT00039130	Leukemia Lymphoma	filgrastim rituximab cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... etoposide ifosfamide leucovorin calc... methotrexate prednisone vincristine sul... Allopurinol	16 Years -	Alliance for Clinical Trials in Oncology
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00003567	Brain and Centr... Lymphoma Unspecified Adu...	filgrastim sargramostim therapeutic aut... O6-benzylguanin... carmustine temozolomide in vitro-treate...	18 Years - 70 Years	Case Comprehensive Cancer Center
Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas	NCT00003113	Lymphoma	filgrastim cyclophosphamid... etoposide lomustine procarbazine hy... radiation thera...	60 Years -	Case Comprehensive Cancer Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer	NCT00006368	Brain and Centr... Breast Cancer Gastrointestina... Islet Cell Tumo... Lung Cancer Lymphoma Melanoma (Skin) Neoplastic Synd...	yttrium Y 90-ed...	18 Years -	Novartis
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant	NCT00002657	Lymphoma Multiple Myelom...	bleomycin sulfa... recombinant int... cyclophosphamid... cytarabine doxorubicin hyd... etoposide methotrexate prednisone vincristine sul... conventional su... radiation thera...	15 Years -	SWOG Cancer Research Network
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00003567	Brain and Centr... Lymphoma Unspecified Adu...	filgrastim sargramostim therapeutic aut... O6-benzylguanin... carmustine temozolomide in vitro-treate...	18 Years - 70 Years	Case Comprehensive Cancer Center
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma	NCT00005959	Lymphoma	filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	18 Years -	National Cancer Institute (NCI)
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202	NCT00896662	Lymphoma Solid Tumor	immunologic tec... laboratory biom... pharmacological...	18 Years -	Vanderbilt-Ingram Cancer Center
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases	NCT00376519	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo...	cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra...	18 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia	NCT00004898	Leukemia Lymphoma	filgrastim cyclophosphamid... etoposide peripheral bloo... radiation thera...	- 65 Years	Northwestern University
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	NCT00010192	B-cell Adult Ac... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ...	rituximab aldesleukin laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers	NCT00619645	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclosporine fludarabine pho... mycophenolate m... allogeneic hema... peripheral bloo...	18 Years - 120 Years	University of California, Davis
SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma	NCT00900484	Lymphoma	biologic sample... immunohistochem... laboratory biom...	16 Years -	SWOG Cancer Research Network
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	NCT00278408	Lymphoma	filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... radiation thera...	18 Years - 60 Years	German High-Grade Non-Hodgkin's Lymphoma Study Group

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: